|
Iniesta Navalon C, Rios-Saorin M, Rentero-Redondo L, Nicolas-de Prado I, Gomez-Espin R, Urbieta Sanz E. Impact of ustekinumab exposure on clinical outcomes during induction in inflammatory bowel disease. Rev Esp Enferm Dig. 2024 Dec 4. doi: 10.17235/reed.2024.10521/2024. Online ahead of print. PubMed PMID: 39629805.
AÑO: 2024; IF: 2.7
|
39629805
|
Diaz LS, Navalon CI, Espin RG, Prado IN, Redondo LR. Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2023 Aug-Sep;46(7):504-511. doi: 10.1016/j.gastrohep.2022.10.019. Epub 2022 Nov 15. English, Spanish. PubMed PMID: 36400260.
AÑO: 2023; IF: 2.2
|
|
Gomez Espin R, Nicolas De Prado I, Gil Candel M, Gonzalez Carrion M, Rentero Redondo L, Iniesta Navalon C. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study. Rev Esp Enferm Dig. 2021 Feb;113(2):110-115. doi: 10.17235/reed.2020.7124/2020. PubMed PMID: 33213170.
AÑO: 2021; IF: 2.389
|
|
Iniesta Navalon C, Gil Candel M, Salar Valverde I, Nicolas de Prado I, Gomez Espin R, Rentero Redondo L. Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival. Rev Esp Enferm Dig. 2021 Nov;113(11):770-775. doi: 10.17235/reed.2021.7638/2020. PubMed PMID: 33486961.
AÑO: 2021; IF: 2.389
|
|
Gil Candel M, Gascon Canovas JJ, Gomez Espin R, Nicolas de Prado I, Rentero Redondo L, Urbieta Sanz E, Iniesta Navalon C. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enferm Dig. 2020 Aug;112(8):590-597. doi: 10.17235/reed.2020.6857/2020. PubMed PMID: 32686429.
AÑO: 2020; IF: 2.086
|